Education
About Us
Working with TipRanks
Follow Us
Abivax SA (DE:2X1)
XETRA:2X1
2X1 Stock Chart & Stats
€112.20
-€0.05(-0.72%)
At close: 4:00 PM EST
€112.20
-€0.05(-0.72%)
Day’s Range― - ―
52-Week Range€4.58 - €132.20
Previous CloseN/A
Volume500.00
Average Volume (3M)891.00
Market Cap
€8.73B
Enterprise Value€8.93B
Total Cash (Recent Filing)€60.95M
Total Debt (Recent Filing)€98.71M
Price to Earnings (P/E)―
Beta>-0.01
Next Earnings
Mar 23, 2026EPS Estimate
-1.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.10
Shares Outstanding79,072,624
10 Day Avg. Volume1,388
30 Day Avg. Volume891
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)10.50
Price to Sales (P/S)39.49
P/FCF Ratio-2.75
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€130.00Price Target Upside15.86% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Platform And Diversified Clinical PipelineOwning a proprietary discovery platform and multiple clinical-stage candidates (ABX464 for IBD and HIV applications) provides durable upside through multi-indication development, licensing or partnerships. Platform-driven pipelines enable repeated R&D productivity over years.
Strong Cash Position Supporting RunwayA strong cash balance provides multi-month runway to advance clinical programs and reach regulatory or partnership milestones without immediate dilution. For a clinical-stage biotech, liquidity longevity materially reduces binary financing risk and supports strategic options.
Revenue Growth With Favorable Gross MarginsRecent top-line growth combined with favorable gross margins indicates the company can scale revenue efficiently and control direct costs. Sustained revenue expansion with healthy gross margins improves long-term funding prospects and attractiveness to partners or acquirers.
Bears Say
Persistent UnprofitabilityOngoing negative EBIT and net losses reflect structural profitability challenges. Persistent unprofitability forces continued capital raises or partner dependence, reducing strategic flexibility and increasing dilution risk for shareholders over the medium term.
Negative Operating And Free Cash FlowNegative operating and free cash flow indicate the core business does not yet generate self-sustaining cash, creating reliance on financing activity. This elevates execution risk if capital markets tighten and can slow program advancement or force unfavorable funding terms.
High Leverage And Low Equity RatioElevated leverage raises fixed obligations and reduces financial flexibility, particularly risky for a clinical-stage biotech with binary R&D outcomes. High debt increases refinancing and covenant risk, constraining ability to invest in multiple programs simultaneously.
Abivax SA News
2X1 FAQ
What was Abivax SA’s price range in the past 12 months?
Abivax SA lowest stock price was €4.58 and its highest was €132.20 in the past 12 months.
What is Abivax SA’s market cap?
Abivax SA’s market cap is €8.73B.
When is Abivax SA’s upcoming earnings report date?
Abivax SA’s upcoming earnings report date is Mar 23, 2026 which is in 28 days.
How were Abivax SA’s earnings last quarter?
Abivax SA released its earnings results on Dec 15, 2025. The company reported -€2.1 earnings per share for the quarter, missing the consensus estimate of -€0.678 by -€1.422.
Is Abivax SA overvalued?
According to Wall Street analysts Abivax SA’s price is currently Undervalued.
Does Abivax SA pay dividends?
Abivax SA does not currently pay dividends.
What is Abivax SA’s EPS estimate?
Abivax SA’s EPS estimate is -1.3.
How many shares outstanding does Abivax SA have?
Abivax SA has 79,072,624 shares outstanding.
What happened to Abivax SA’s price movement after its last earnings report?
Abivax SA reported an EPS of -€2.1 in its last earnings report, missing expectations of -€0.678. Following the earnings report the stock price went down -9.152%.
Which hedge fund is a major shareholder of Abivax SA?
Currently, no hedge funds are holding shares in DE:2X1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Abivax SA
ABIVAX Société Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France. Its principal products include ABX464 that is in Phase IIb clinical trials for the treatment of ulcerative colitis and Crohn's Disease, as well as for COVID-19; Phase IIa clinical trial for the treatment of rheumatoid arthritis diseases; and has completed Phase IIa clinical trial for the treatment of viral remission in patients with HIV. It also develops ABX 196, an immune enhancer candidate that is in Phase 1/2 clinical trials for the treatment of hepatocellular cancer. In addition, the company engages in the research programs for the treatment of Dengue fever, influenza, and respiratory syncytial virus. ABIVAX Société Anonyme has license contracts with the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. The company was incorporated in 2013 and is headquartered in Paris, France.
2X1 Stock 12 Month Forecast
Average Price Target
€130.00
▲(15.86% Upside)
Technical Analysis
Options Prices
Currently, No data available
---